Topical Minoxidil vs Topical Finasteride in Androgenetic Alopecia (AGA)

Background: Pathophysiology

Mechanisms of Action

Topical Minoxidil

• A potassium channel opener originally developed as an antihypertensive; incidentally observed to cause hypertrichosis
• Exact mechanism in hair follicles is unknown
• Enhances follicular size → thicker hair shafts
• Stimulates and prolongs the anagen phase of the hair cycle → more and longer hairs
• Patients with higher scalp sulfotransferase enzyme activity respond better (may be a future predictive biomarker)
• Available as 2% solution (approved for women), 5% solution and 5% foam (recommended for men due to greater efficacy)
• Vertex balding responds better than frontal balding
• Katzung's Basic and Clinical Pharmacology, 16th Ed.

Topical Finasteride

• Selective type II 5α-reductase inhibitor → blocks conversion of testosterone → DHT
• Balding scalp areas have elevated DHT levels and smaller follicles vs non-balding areas
• Topical spray formulation (0.25% or 2.2 mg/mL) delivers drug locally to hair follicles
• Produces less systemic DHT suppression than oral finasteride (key advantage for side effect profile)
• Goldman-Cecil Medicine notes: "Finasteride topical spray is as effective as oral finasteride with less impact on dihydrotestosterone levels"

Efficacy: Head-to-Head Evidence

Monotherapy Comparisons

• At 24 weeks: dutasteride 0.5 mg/day led all agents; oral finasteride 1 mg and topical minoxidil 5% showed comparable total hair count gains
• At 48 weeks: oral finasteride 1 mg emerged as significantly more effective than topical minoxidil 2% for terminal hair count (+32.1 hairs/cm², p < 0.05); topical minoxidil 5% performed better than 2% at all time points

• Dutasteride 0.5 mg/day was the most effective overall
• Among FDA-approved treatments: topical minoxidil 5% was the most effective topical monotherapy
• Finasteride 1 mg/day was the most effective oral option
• Topical finasteride (mesotherapy/spray) showed efficacy comparable to oral finasteride in several metrics

Combination Therapy: Additive Benefit

• Group A: Topical minoxidil 5% + topical finasteride 0.25% spray
• Group B: Topical finasteride 0.25% alone
• Group C: Topical minoxidil 5% alone

• Group A (combination): +56 hairs/cm² at 3 months, +81 hairs/cm² at 6 months (both p < 0.001 vs baseline)
• 79% of Group A achieved GPAS ≥2 vs 8% (finasteride alone) and 41% (minoxidil alone) at 6 months
• No significant differences in serum hormones (FSH, LH, testosterone) across groups — confirming topical finasteride's minimal systemic absorption

• Topical minoxidil–finasteride combination (MFX) was superior to minoxidil monotherapy for hair density (MD = +9.22 hairs/cm², p = 0.04), hair diameter (MD = +2.26 μm, p = 0.005), and global photographic assessment (MD = 0.79, p < 0.00001)
• Short-term studies (≤12 weeks) often show no significant benefit of combination vs monotherapy; longer trials (≥24 weeks) show clear superiority of combination

Safety Profile

Topical Minoxidil

Topical Finasteride

Special Populations

Practical Summary

Key Takeaways

1. Both agents are effective as monotherapy in male AGA, with comparable efficacy at 24 weeks; oral finasteride shows edge over topical minoxidil 2% (not 5%) at 48 weeks.
2. Topical finasteride delivers efficacy equivalent to oral finasteride with substantially fewer systemic (sexual) side effects — making it a preferable route when finasteride is indicated.
3. Combination of topical minoxidil 5% + topical finasteride 0.25% is significantly superior to either monotherapy, with 79% of patients achieving meaningful photographic improvement at 6 months (vs 41% minoxidil alone, 8% finasteride alone).
4. Topical minoxidil remains the only FDA-approved topical option for women; finasteride in any form is contraindicated in women of childbearing potential.
5. Both treatments require continuous use — cessation leads to reversal of gains.

• Katzung's Basic and Clinical Pharmacology, 16th Ed. — Minoxidil & Finasteride sections
• Goodman & Gilman's Pharmacological Basis of Therapeutics — Androgenic Alopecia section
• Goldman-Cecil Medicine — Treatment of Androgenetic Alopecia
• Gupta AK et al. JAMA Dermatol. 2022;158:266–274 [PMID 35107565] — Network meta-analysis, 23 RCTs, minoxidil vs 5α-reductase inhibitors
• Gupta AK et al. J Cosmet Dermatol. 2025 [PMID 40586152] — Updated NMA, 33 studies, 19 comparators
• Rossi A & Caro G. J Cosmet Dermatol. 2024 [PMID 37798906] — RCT, combination vs monotherapy
• Li et al. Front Med. 2025 [PMID 41127390] — Meta-analysis of 7 RCTs, combination vs minoxidil monotherapy

Why Dispense into Cap First

• The foam melts immediately on contact with warm fingers and scalp
• You lose product to your hands and hair before it reaches the scalp skin
• Application becomes uneven

• The foam stays intact long enough to position it on the scalp
• You can part your hair and apply it in sections more precisely
• Less product is wasted

Correct Application Technique

1. Half-capful (about 1 g) = one dose for men; use the full cap measure marked on the product
2. Dispense into the upturned cap — keep it cool (don't hold in your warm palm)
3. Part your hair to expose the scalp in the target area (vertex/crown primarily)
4. Tip the cap directly onto the scalp sections, depositing the foam at the scalp surface
5. Use fingertips (not palms) to spread and lightly massage into the scalp — not into the hair shafts
6. Wash hands immediately after

Key Points

• Target the scalp, not the hair — the active site is the hair follicle, not the hair shaft; massaging into the hair wastes drug
• Let it dry naturally for ~4 hours before washing; do not use a hairdryer directly on the area
• Apply to a dry scalp — wet hair dilutes the foam and reduces contact time
• The foam formulation is specifically designed to reduce propylene glycol exposure (a common irritant in the solution), so it's gentler for sensitive scalps

1. Regulatory Status in Germany (Most Likely Reason)

• A compounded/magistral preparation (from a compounding pharmacy), or
• A licensed product in only a few countries (e.g., Italy's Brotzu formulation)

2. Sequential Trial Logic (Evidence-Based Rationale)

• Start monotherapy → assess response → add second agent if inadequate
• This isn't irrational — it also tells you which agent is working if combination is later started
• The combination RCT evidence (Rossi 2024) is still relatively recent pilot data (n=42), and the meta-analysis (Li et al. 2025) only pooled 7 RCTs with N=396 — not yet large enough to have changed most national guidelines

3. The Non-Responder Problem Is Real

• ~30% of AGA patients are poor responders to 5α-reductase inhibitors — likely due to androgen receptor variants or follicular sensitivity differences
• If he doesn't respond to finasteride at all, the combined benefit of adding minoxidil to finasteride may not apply to him the same way it does in responders
• The dermatologist may be reasoning: "Let's see what minoxidil alone does before layering complexity"

4. Practical / Cost Considerations

• A compounding prescription (Rezeptur) at a compounding pharmacy
• Higher out-of-pocket cost (not covered by GKV/statutory insurance)
• Minoxidil foam (Regaine) is over-the-counter and cheaper

5. What the Evidence Actually Says (Honestly)

What Your Cousin Could Do

1. Ask the dermatologist directly: "Given the evidence for combination therapy, why are we not combining minoxidil with finasteride simultaneously?" — a good dermatologist will engage with this.
2. Give minoxidil 6 months before concluding it doesn't work. The switch is reasonable — finasteride non-response doesn't predict minoxidil non-response (completely different mechanisms).
3. If minoxidil shows partial response, advocate for adding topical finasteride back — this time as combination. The Rossi 2024 trial used exactly 5% topical minoxidil + 0.25% topical finasteride spray.
4. Consider oral finasteride 1 mg/day — it has the strongest long-term evidence base and is licensed in Germany. If systemic side effect concern was why topical was used, that's worth a frank discussion.
5. Ask about a compounding prescription (Rezepturrezept) combining both in one formulation — some German compounding pharmacies can prepare a minoxidil + finasteride combined solution, which improves adherence.

Bottom Line

The Cap-to-Scalp Transfer Method

1. Dispense into the upturned cap — press the can nozzle while holding the cap under it, foam collects in the cap
2. Part your hair with your other hand to expose a section of scalp
3. Tilt/tip the cap so the foam slides directly onto that exposed scalp section — like pouring it out gently onto the skin
4. Repart to another section and repeat until the dose is distributed
5. Then use fingertips to lightly spread what's already on the scalp — at this point you're just evening it out, not transferring from fingers

The Key Principle

• Your palm/fingers are warm → foam liquefies and absorbs into your skin before reaching the scalp
• The scalp is the target, not your fingertips
• You lose a meaningful amount of active drug if it melts in your hand first

Visual Analogy